newzzz
Back to recent news

News Archive

Past news

DiaSorin Molecular Receives Additional BARDA Funding in Support of Submitting the Simplexa™ COVID-19 Direct and the Simplexa™ COVID-19 & Flu A/B Direct kits for FDA 510(k) Clearance

Cypress, California (USA) – January 13, 2021 – DiaSorin Molecular LLC, a subsidiary of DiaSorin S.p.A. (FTSE MIB:DIA), announced today that it has received additional federal funding from the Biomedical Advanced Research and Development Authority (BARDA),…

DiaSorin Molecular’s Simplexa™ COVID-19 Direct Molecular Test CE Marked for Saliva Specimens

Cypress, Calif. (September 17, 2020) – DiaSorin Molecular LLC announced today that it has attained CE Marking for the addition of saliva specimens for use with the Simplexa COVID-19 Direct assay….

DiaSorin Molecular receives FDA clearance for the Simplexa™ Flu A/B & RSV Direct Gen II Assay. A partner to run with the Simplexa™ COVID-19 Direct assay.

Cypress, Calif. (September 8, 2020) – DiaSorin Molecular LLC announced today that it has received FDA Clearance for its Simplexa™ Flu A/B & RSV Direct Gen II kit….

DiaSorin Molecular CE marks their new Simplexa™ Flu A/B & RSV Direct Gen II Assay to run with the Simplexa™ COVID-19 Direct assay

Cypress, Calif. (July 7, 2020) – DiaSorin Molecular LLC announced today that it has CE marked its Simplexa™ Flu A/B & RSV Direct Gen II kit….

DiaSorin Molecular’s Simplexa™ Congenital CMV Direct Assay Attains CE Mark

Cypress, Calif. (June 15, 2020) – DiaSorin Molecular LLC announced today that it has received CE marking for its Simplexa™ Congenital CMV Direct kit. The new molecular diagnostic test enables direct detection of cytomegalovirus DNA in both saliva swab and urine specimens from babies up to 21 days old….
Back to recent news